GlassScriptPhysician profile
Kristen Connolly
NPI 1427782903
$6,259.61
in general payments reported to CMS, 2019-2025
27 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,631 · 2023: $1,466 · 2024: $1,158 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.73 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,208.43 | 2022-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $765.01 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $719.65 | 2022-2025 | |
| Astellas Pharma US INC | $702.05 | 2023-2025 | Xtandi, Myrbetriq, Veozah |
| Janssen Biotech, INC. | $204.23 | 2022-2025 | Erleada, Akeega, Balversa |
| Merck Sharp & Dohme LLC | $189.09 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Endo Pharmaceuticals INC. | $145.10 | 2022-2024 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $138.32 | 2024-2025 | Adstiladrin |
| Novo Nordisk INC | $124.87 | 2025 | Wegovy |
| Paratek Pharmaceuticals, INC. | $121.60 | 2024 | Nuzyra |
| Endo USA, INC. | $119.54 | 2024-2025 | Xiaflex, Aveed |
| Boston Scientific Corporation | $89.56 | 2022-2025 | Axonics |
| Convatec INC. | $88.97 | 2023-2024 | |
| Sanofi Pasteur INC. | $87.73 | 2022 | |
| Urogen Pharma, INC. | $87.45 | 2023-2025 | Jelmyto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $83.21 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $63.94 | 2022-2023 | Lynparza |
| Karl Storz Endoscopy-America | $58.39 | 2022-2023 | N.A. |
| Bayer Healthcare Pharmaceuticals INC. | $47.72 | 2024 | |
| Myovant Sciences INC. | $47.70 | 2022 | |
| Urovant Sciences INC | $32.17 | 2022 | |
| Pfizer INC. | $30.69 | 2023 | |
| Olympus America INC. | $24.52 | 2023 | Itind System |
| Myriad Genetic Laboratories, INC. | $23.65 | 2025 | Prolaris |
| Tolmar Pharmaceuticals, INC. | $19.88 | 2022 | |
| Procept Biorobotics Corporation | $19.58 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.56 | 2023 | Oxlumo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Connolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.